1 Changing incidence of CNS HIV-related diseases in the EuroSIDA cohort. d´Arminio Monforte A, Cinque P, Mocroft A, Goebel F-D, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren JD, for the EuroSIDA Study Group.
Ann Neurol. 2004; 55:320-328 abstract

2 Lipid profiles in HIV-1-infected individuals receiving combination antiretroviral therapy: are different protease inhibitors or non-nucleoside reverse transcriptase inhibitors associated with different lipid profiles? Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d’Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P.
J Infect Dis. 2004;189 abstract

3 Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Ostergaard C, Benfield T, Lundgren JD and Eugen-Olsen J.
Scand J Infect Dis. 2004;36:14-19abstract

4 Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. Kirk O and Lundgren JD.
Cur Opin Infect Dis. 2004;17:33-37 abstract

5 Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs.
Lundgren JD, Phillips AN.
BMJ. 2004;328(7434):253 abstract

6 The PLATO Collaboration. Predictors of CD4 count trend and mortality among HIV-1 - infected patients with virologic failure to all three antiretroviral drug classes. Writing committee: Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe, F Gill J, Castelli F, Phillips AN.
Lancet. 2004;364:51-62 abstract

7 HIV survival benefit associated with earlier antiviral therapy. Mocroft A, Phillips AN, Lundgren JD.
Ann Inter Med. 2004;140(7):578-9 abstract

8 Forscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J.
AIDS 2004;18(7):1076-78 abstract

9 The Changing pattern of Kaposi´s sarcoma in patients with HIV - 1994-2003. The EuroSIDA Study. Mocroft A, Kirk O, Clumeck N, Gargalianos P, Trocha H, Chentsova N, Antunes F, Stellbrink H-J, Phillips AN, Lundgren JD for the EuroSIDA study group.
Cancer 2004; 100:2644-2654 abstract

10 Predictors of immunological failure after initial response to HAART in HIV-1 infected adults: a EuroSIDA study. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AE, Panos G, Mercey D, Machala L, Horban A, and Lundgren JD; EuroSIDA study group.
J Infect Dis. 2004 Jul 1;190(1):148-55 abstract

11 Reduktion af aids og dødsrater i EuroSIDA-studiet. Et observationsstudie. Kirk O, Mocroft A and Lundgren JD for the EuroSIDA study.
Ugeskrift Laeger. 2004;166(26-31):2571-6 abstract

12 HIV cohort collaborations: proposal for harmonization of data exchange. Kjaer J and Ledergerber B.
Antivir. Ther. 2004;9:631-3 abstract

13 Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. Collaboration of HIV Cohorts, writing committee: Phillips AN, Ledergerber B, Lundgren JD, Hogg B, d'Arminio Monforte A, Castelli F, Walker S, Staszewski S, Thiébaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D.
J Infect Dis 2004;190:675-87 abstract

14 Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe. A EuroSIDA study, 1994-2000. Yust I, Fox Z, Burke M, Johnson AM, Tuner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O, for the EuroSIDA study.
Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):550-9 abstract

15 Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group.
AIDS. 2004 Sep 3;18(13):1795-804 abstract

16 Cardio- and Cerebrovascular Events in HIV-Infected Persons. The Data Collection
o­n Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
Writing Committee: d'Arminio Monforte A, Sabin CA, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Phillips AN, Lundgren JD, and Friis-Moller N.
AIDS 2004, 18:1811-1817 abstract

17 HIV remains a deadly disease. Lundgren JD
HIV med. 2004;5:251-2 abstract

18 Attenuation of the blood bacterial load by pre-treatment with G-CSF protects from fatal outcome and brain damage in Streptococcus pneumoniae meningitis in rats. Brandt CT, Lundgren JD, Lund SP, Frimodt-Møller N, Christensen T, Benfield T, Espersen F, Hougaard DM and Østergaard C.
Infect Immun. 2004 Aug;72(8):4647-53 abstract

19 Starting antiretroviral therapy: why, when and response to HAART [review]. Mocroft A, Lundgren JD
J Antimicrob Chemother. 2004 Jul;54(1):10-3. Epub 2004 May 26. Review abstract

20 Is the Salk principle still viable for the design of an effective HIV vaccine? [editorial]. Lundgren JD
HIV Med. 2004 Sep;5(5):315-6 abstract

21 Current Epidemiology of Pneumocystis Pneumonia. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson D, Frederick T, Huang L, Beard C and Kaplan JE
Emerg Infect Dis. 2004 Oct;10(10):1713-20. abstract

22 Baseline Resistance and Virologic Outcome in Patients with Virologic Failure who start a Regimen Containing Abacavir: EuroSIDA Study. Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjær J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L o­n behalf of the EuroSIDA study group.
Antivir Ther. 2004 Oct;9(5):787-800. abstract

23 Changes in hospital admissions across Europe:1994-2003. Results from the EuroSIDA study. Mocroft A, d’Arminio Monforte A, Kirk O, Johnson MA, Friis-Moller N,
Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD for the EuroSIDA study group.
HIV Med. 2004 Nov;5(6):437-47. abstract

24 A prospective, blinded study of quantitative touch-down PCR using oral washes for diagnosis of Pneumocystis Pneumonia in patients with HIV infection. Larsen HH, Huang L, Kovacs JA, Crothers K, Silcott VA, Morris A, Turner JR, Beard CB, Masur H, and Fischer SH.
J Infect Dis. 2004 May 1;189(9):1679-83. Epub 2004 Apr 16 abstract

25 Time to virological failure of three classes of antiretrovirals after initiation of HAART : Results from the EuroSIDA study group. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen A-B E, Phillips AN, Lundgren JD for the EuroSIDA study group
J Infect Dis. 2004 Dec 1;190(11):1947-56. Epub 2004 Oct 28. abstract

26 Causes of death in HIV infection:the key determinant to define the clinical response to anti-HIV therapy. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; for the EuroSIDA study group.
AIDS. 2004 Nov 19;18(17):2333-2337 abstract

27 Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. Roge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.
HIV med. 2004 Sep;5(5):344-51 abstract

28 Updated European recommendations for the clinical use of HIV drug resistance testing. Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmitt JC, Schuurmann R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R and
Perrin L.
Antivir Ther. 2004 9:829-848 abstract

29 Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. May M, Royston P, Egger M, Justice AC, Sterne JAC and the ART Cohort Collaboration. Statistics in Medicine 2004 23: 2375-98.

Updated: 16 Sep 2009